Literature DB >> 29862166

Current approaches and future directions in the management of pterygium.

Kyoung Woo Kim1, Jae Chan Kim2.   

Abstract

Pterygium, a common ocular surface disorder, has a complex pathophysiology that may mimic tumorigenesis. There is altered expression of cell cycle/proliferation-related factors in pterygium tissues. Therefore, similar to cancer treatments, the management of pterygium ought to be multifactorial based on the patient's condition. Current therapeutic methods for pterygium are focused on surgical resection in conjunction with antimetabolite use, in addition tissue graft is usually performed in the context of the avoidance of bare sclera. However, future directions in the management of pterygia will likely focus on genetic approaches. This perspective views the pathogenesis of pterygium, its existing therapies as well as current and future challenges in its treatment.

Entities:  

Keywords:  future directions; pterygium; recurrence; tumor

Year:  2018        PMID: 29862166      PMCID: PMC5957019          DOI: 10.18240/ijo.2018.05.01

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  12 in total

1.  Expression of p27(KIP1) and cyclin D1, and cell proliferation in human pterygium.

Authors:  Satoru Kase; Shuji Takahashi; Izuru Sato; Katsuya Nakanishi; Kazuhiko Yoshida; Shigeaki Ohno
Journal:  Br J Ophthalmol       Date:  2006-12-19       Impact factor: 4.638

2.  Proliferative activity and p53 expression in primary and recurrent pterygia.

Authors:  I Chowers; J Pe'er; E Zamir; N Livni; M Ilsar; J Frucht-Pery
Journal:  Ophthalmology       Date:  2001-05       Impact factor: 12.079

3.  Expression of p63 and p16 in primary and recurrent pterygia.

Authors:  Fernando S Ramalho; Claudia Maestri; Leandra N Z Ramalho; Alfredo Ribeiro-Silva; Erasmo Romão
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-08       Impact factor: 3.117

4.  A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells.

Authors:  Hyun Sook Hong; Jungsun Lee; EunAh Lee; Young Sam Kwon; Eunkyung Lee; Woosung Ahn; Mei Hua Jiang; Jae Chan Kim; Youngsook Son
Journal:  Nat Med       Date:  2009-03-08       Impact factor: 53.440

5.  MicroRNA-215 Regulates Fibroblast Function: Insights from a Human Fibrotic Disease.

Authors:  Wanwen Lan; Silin Chen; Louis Tong
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  Upregulated stromal cell-derived factor 1 (SDF-1) expression and its interaction with CXCR4 contribute to the pathogenesis of severe pterygia.

Authors:  Kyoung Woo Kim; Soo Hyun Park; Seung Hoon Lee; Jae Chan Kim
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-11-01       Impact factor: 4.799

7.  Expression of CREB in primary pterygium and correlation with cyclin D1, ki-67, MMP7, p53, p63, Survivin and Vimentin.

Authors:  Mario Nubile; Claudia Curcio; Manuela Lanzini; Roberta Calienno; Manuela Iezzi; Alessandra Mastropasqua; Marta Di Nicola; Leonardo Mastropasqua
Journal:  Ophthalmic Res       Date:  2013-07-03       Impact factor: 2.892

8.  Overexpression of angiogenin in pterygium body fibroblasts and its association with proliferative potency.

Authors:  Kyoung Woo Kim; Soo Hyun Park; Sung Wook Wee; Jae Chan Kim
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-24       Impact factor: 4.799

Review 9.  Fibroblast biology in pterygia.

Authors:  Kyoung Woo Kim; Soo Hyun Park; Jae Chan Kim
Journal:  Exp Eye Res       Date:  2016-01       Impact factor: 3.467

10.  Management of complicated multirecurrent pterygia using multimicroporous expanded polytetrafluoroethylene.

Authors:  Kyoung Woo Kim; Jae Chan Kim; Jun Hyung Moon; Hyun Koo; Tae Hyung Kim; Nam Ju Moon
Journal:  Br J Ophthalmol       Date:  2013-03-15       Impact factor: 4.638

View more
  9 in total

1.  Role of oxidative stress and vascular endothelial growth factor expression in pterygium pathogenesis and prevention of pterygium recurrence after surgical excision.

Authors:  Sameh Mohamed Elgouhary; Hesham Fouad Elmazar; Mariana Ibrahim Naguib; Noha Rabie Bayomy
Journal:  Int Ophthalmol       Date:  2020-06-06       Impact factor: 2.031

Review 2.  Pterygium: an update on pathophysiology, clinical features, and management.

Authors:  Toktam Shahraki; Amir Arabi; Sepehr Feizi
Journal:  Ther Adv Ophthalmol       Date:  2021-05-31

Review 3.  How to minimize pterygium recurrence rates: clinical perspectives.

Authors:  Raffaele Nuzzi; Federico Tridico
Journal:  Clin Ophthalmol       Date:  2018-11-19

4.  Management of double-head pterygium with conjunctival autograft and primary closure.

Authors:  Tobias Röck; Karl Ulrich Bartz-Schmidt; Daniel Röck
Journal:  Int Med Case Rep J       Date:  2020-04-01

5.  A Retrospective Study to Compare the Recurrence Rate After Treatment of Pterygium by Conjunctival Autograft, Primary Closure, and Amniotic Membrane Transplantation.

Authors:  Tobias Röck; Matthias Bramkamp; Karl Ulrich Bartz-Schmidt; Daniel Röck
Journal:  Med Sci Monit       Date:  2019-10-24

Review 6.  Recurrent Pterygium: A Review.

Authors:  Leila Ghiasian; Bijan Samavat; Yasaman Hadi; Mona Arbab; Navid Abolfathzadeh
Journal:  J Curr Ophthalmol       Date:  2022-01-06

7.  Application of a Deep Learning System in Pterygium Grading and Further Prediction of Recurrence with Slit Lamp Photographs.

Authors:  Kuo-Hsuan Hung; Chihung Lin; Jinsheng Roan; Chang-Fu Kuo; Ching-Hsi Hsiao; Hsin-Yuan Tan; Hung-Chi Chen; David Hui-Kang Ma; Lung-Kun Yeh; Oscar Kuang-Sheng Lee
Journal:  Diagnostics (Basel)       Date:  2022-04-02

8.  Immunohistochemical study of STAT3, HIF-1α and VEGF in pterygium and normal conjunctiva: Experimental research and literature review.

Authors:  Shiqi Dong; Xiying Wu; Yuting Xu; Guohua Yang; Ming Yan
Journal:  Mol Vis       Date:  2020-07-26       Impact factor: 2.367

Review 9.  Pterygium-The Good, the Bad, and the Ugly.

Authors:  Sara I Van Acker; Bert Van den Bogerd; Michel Haagdorens; Vasiliki Siozopoulou; Sorcha Ní Dhubhghaill; Isabel Pintelon; Carina Koppen
Journal:  Cells       Date:  2021-06-22       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.